Data from the ENDEAVOUR trial (NCT01568866) has shown that using carfilzomib plus dexamethasone (Kd) is more effective in treating relapsed/refractory multiple myeloma (MM) than the standard combination of bortezomib and dexamethasone (Vd). Here, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, speaking from the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, discusses using Kd therapy to treat patients outside of the clinical trial setting. He discusses ways to minimize risk, such as monitoring blood pressure rigorously and limiting fluid intake, as well as ways to manage long-term administration of Kd therapy.
Using carfilzomib/dexamethasone for MM in the real world
